arrow
A

Alison C. MacKinnon

galecto biotech aps
H指数:42
被引数:8,057

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Orally Available Halothiazole Glycomimetic as a Cancer-Targeting Dual Galectin-1 and Galectin-3 Inhibitor

一种口服可用的卤代噻唑类糖模拟物作为靶向癌细胞的半乳糖凝集素-1和半乳糖凝集素-3双重抑制剂

2026-04-290
PRE
Retraction Notice to: “CSF1 Restores Innate Immunity After Liver Injury in Mice and Serum Levels Indicate Outcomes of Patients With Acute Liver Failure” Gastroenterology 2015;149:1896–1909.e14

撤稿通知: “CSF1 Restores Innate Immunity After Liver Injury in Mice and Serum Levels Indicate Outcomes of Patients With Acute Liver Failure” Gastroenterology 2015;149:1896–1909.e14

2025-10-230
PRE
Development of a multi-biomarker risk score based on serum proteins by the Prognostic Lung Fibrosis Consortium (PROLIFIC)
2024-10-300
PRE
Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer

发现选择性和口服Galectin-1抑制剂GB1908作为肺癌的潜在治疗方法

2024-05-287
PRE
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)
2023-01-1525
OAAI
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease

用于治疗纤维化疾病的首个高效且可口服的Galectin-3抑制剂的发现和优化

2022-09-2647
OAAI
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
2020-11-19141
OAAI
An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade

口服活性Galectin-3拮抗剂抑制肺腺癌生长并增强对PD-L1阻滞的反应

2019-04-01117
OAAI